WeTrials
Recruiting

A Trial to Evaluate Deoxyribonucleic) in BRAF (V-raf Murine Sarcoma Viral Oncogene Homolog B1)-Altered Glioma During Treatment With Plixorafenib Alone or With Retifanlimab

What is this study?

This study is testing special medications to treat a type of brain tumor called a glioma that has a specific genetic change. Doctors want to see how well these new treatments work by tracking tiny pieces of cancer material in the blood and spinal fluid.

Who can participate?

You might be able to join if you have a BRAF-V600E mutant glioma that has not responded well to past treatments. However, you cannot join if you have previously taken certain types of targeted cancer drugs or immunotherapy, or if you have a history of major autoimmune diseases.

What will happen?

Participants will receive either a targeted cancer medication called plixorafenib alone, or in combination with an immunotherapy medication called retifanlimab. Doctors will also monitor your response to the treatment by taking blood and spinal fluid samples over time.

Where and when?

This study is currently recruiting participants in Baltimore, Maryland, and New York, New York, in the United States. It is in the very early stages of testing.

Key Points
  • 1Tests new treatments for a specific type of brain tumor called a glioma.
  • 2Combines a targeted medication with an optional immunotherapy drug to help fight the cancer.
  • 3Involves regular check-ups and sample collections to see how well the treatment is working.

Related video

MD Anderson's Dr. Janku on earlier plixorafenib (PLX8394) results and ctDNA findings (2020)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
BRAF V600E Mutation

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.